Skip to main content
OpenTrials
Completed

NCT Number: NCT00363844

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Chugoku Region, Chugoku, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with type 2 diabetes mellitus on diet and exercise therapy

Exclusion criteria

  • Patients with type 1 diabetes mellitus

Treatment and study plan

sitagliptin phosphate

Drug

50 mg QD or 100 mg QD for 12 months

Primary outcomes

  1. safety

    Time frame: 52 weeks

  2. tolerability

    Time frame: 52 weeks

Secondary outcomes

  1. HbA1c

    Time frame: 52 weeks

  2. Plasma glucose

    Time frame: 52 weeks

Sponsors and collaborators

Lead sponsor

Ono Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients With Type 2 Diabetes Mellitus

Important dates

Study start
2006
Primary completion
2008
First posted
Aug 15, 2006
Registry last updated
Jun 14, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.